The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Thomas KnuijverRob Ter HeineArnt F A SchellekensPaniz HeydariLuc LucasSjoerd WestraMaarten BelgersToon van OosterenRobbert Jan VerkesCornelis Kramers

Published in: Journal of psychopharmacology (Oxford, England) (2024)

The clearance of ibogaine is strongly related to CYPD2D6 genotype. Ibogaine cardiac side effects (QTc time) and cerebellar effects are most likely more driven by ibogaine rather than noribogaine. Future studies should aim at exploring lower doses and/or applying individualized dosing based on CYP2D6 genotype.

Keyphrases

end stage renal disease
chronic kidney disease
heart failure
current status
patient reported outcomes
atrial fibrillation
case control